Latest news with #PeterLawson
Yahoo
7 hours ago
- Business
- Yahoo
Relay Therapeutics has positive read from Celcuity data, says Barclays
After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant Barclays analyst Peter Lawson said the data validate targeting the PI3K pathway in breast cancer, which has a positive read-through for Relay Therapeutics (RLAY). While gedatolisib could represent new competition, the firm continues to see important advantages in Relay's mutant selective approach and keeps an Overweight rating and $17 price target on Relay shares. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on RLAY: Disclaimer & DisclosureReport an Issue Claire Mazumdar Joins Relay Therapeutics as Director Relay Therapeutics Holds 2025 Annual Stockholder Meeting Relay Therapeutics Announces Lease Termination Agreement Relay Therapeutics announces updated data for RLY-2608 with Fulvestrant Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Scotsman
16 hours ago
- Business
- Scotsman
Burness Paull: ‘Refined' three-year strategy paying off as law firm's turnover tops £93 million
'We are already seeing the benefits of the new strategy through a strong start to the current financial year' – Peter Lawson, chairman Sign up to our Scotsman Money newsletter, covering all you need to know to help manage your money. Sign up Thank you for signing up! Did you know with a Digital Subscription to The Scotsman, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... Scottish legal heavyweight Burness Paull said it was already seeing the benefits of a 'refined' three-year growth strategy as it reported annual turnover of more than £93 million. Chairman Peter Lawson hailed a 'solid year of trading' at the firm, which saw growth across all key practice areas. The financial year to the end of March 2025 also witnessed a change of leadership at the firm that saw Mark Ellis assume the role of managing partner midway through the period. Advertisement Hide Ad Advertisement Hide Ad Turnover for the year amounted to £93.5m and overall profit was £35.9m as the firm made investments in support of a new three-year strategic growth plan and 'to ensure clients receive the highest quality advice amid ongoing economic uncertainty'. Those figures compare with turnover of £60.1m and profit of £24.3m for the prior, shortened eight-month period after the firm decided to change its year-end following tax reporting reforms and to 'align with market norms'. Peter Lawson is the chairman of law firm Burness Paull which has 700 people, including 95 partners, serving clients from its offices in Aberdeen, Edinburgh and Glasgow. Burness Paull has 700 people, including 95 partners, serving clients from its operations in Aberdeen, Edinburgh and Glasgow. Lawson said: 'A solid year of trading saw growth across all key practice areas, with our corporate M&A, energy, banking and funds, disputes, employment, cyber, and restructuring and insolvency teams performing particularly well. 'When Mark took over as managing partner, we initiated the most rigorous business planning exercise we have ever undertaken as a firm. The result was a refined three-year strategy beginning the 2025/26 financial year that, combined with the investments we have made in our people and infrastructure, offers us a clear roadmap for sustainable, profitable growth over the long term. Advertisement Hide Ad Advertisement Hide Ad 'We are already seeing the benefits of the new strategy through a strong start to the current financial year, which has seen us win instructions from across Scotland, the UK and internationally.' He added: 'It remains a dynamic business environment characterised by increased levels of investor confidence and transactional activity due to falling interest rates, paired with caution around cost pressures and volatility in global trade policy.' Notable client mandates for the year included advising i3 Energy on its takeover by Gran Tierra Energy in a deal valued at £174m, Springfield Properties in relation to its partnership with Barratt to deliver a new village settlement of 3,000 homes at Durieshill on the outskirts of Stirling, and the Scottish Football Association on the sale of UK and international broadcasting rights. Earlier this month, larger peer Brodies said it had racked up its 15th consecutive year of growth, triggering a 5 per cent bonus for hundreds of staff. Advertisement Hide Ad Advertisement Hide Ad The firm's latest results revealed that total revenues rose to £126.7m for the year ending April 30, 2025 - an increase of some 11 per cent from £114.3m the previous year. Operating profit also grew, reaching in excess of £50m, up from £49.2m, with profit per equity partner recorded at £885,296.
Globe and Mail
16-07-2025
- Business
- Globe and Mail
Barclays Reaffirms Their Buy Rating on Iovance Biotherapeutics (IOVA)
Barclays analyst Peter Lawson maintained a Buy rating on Iovance Biotherapeutics today and set a price target of $4.00. The company's shares closed yesterday at $2.01. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Lawson covers the Healthcare sector, focusing on stocks such as Exelixis, Blueprint Medicines, and Kura Oncology. According to TipRanks, Lawson has an average return of -7.3% and a 38.31% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Iovance Biotherapeutics with a $10.00 average price target, representing a 397.51% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target. IOVA market cap is currently $624.5M and has a P/E ratio of -1.63. Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IOVA in relation to earlier this year. Last month, Daniel Gordon Kirby, the CCO of IOVA bought 30,000.00 shares for a total of $55,200.00.
Business Insider
17-06-2025
- Business
- Business Insider
Barclays Remains a Buy on Nurix Therapeutics (NRIX)
In a report released today, Peter Lawson from Barclays maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $31.00. The company's shares closed yesterday at $11.96. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Lawson is an analyst with an average return of -7.3% and a 38.91% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Arcus Biosciences, Iovance Biotherapeutics, and Blueprint Medicines. Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $29.43, representing a 146.07% upside. In a report released yesterday, BTIG also reiterated a Buy rating on the stock with a $35.00 price target. The company has a one-year high of $29.56 and a one-year low of $8.18. Currently, Nurix Therapeutics has an average volume of 995.3K.
BBC News
16-05-2025
- Climate
- BBC News
Thames death in Sunbury could have been prevented
A man who helped save four people caught in a fatal incident on the River Thames said the death of one of the crew could have been 11 October, 68-year-old Peter Lawson was swept down the Little Grey Weir in Sunbury, in Surrey, after his boat capsized and broke in two - his body was found nine days Whiterod told an inquest at Woking Coroner's Court on Friday that Mr Lawson may have been saved if there was an emergency system to shut the Burns, the River Thames area director for the Environment Agency (EA), said while she understood the concern, there was a chance of misuse if there were emergency buttons. Ms Burns, who described operating the weir as "complex", explained that extra safety signs had been put on the weir following the lock box had also been changed since Mr Lawson's death and a copy of the key was kept at the Sunbury EA's safety warning boards for the stretch of the river was red on the day of the incident, and Ms Burns told coroner Scott McDonnell that more work was needed to ensure people understood the agency's said the EA had no power to prevent people going on the river and they did their own local assessments of risk. 'Terrifying' waves The EA's field team leader Steve Scott rushed from his office in Sunbury when he spotted the broken rowing boat float past and got instructions over the phone on how to close the Whiterod told the inquest: "If we had been able to do that immediately, I wouldn't have gone out in my boat and Peter wouldn't have drowned."He said the waves at the weir on that day were "terrifying" and making a "churning, rolling, standing wave".He added that his own boat partially capsized because of the force of the inquest heard that the gate had been open for several days to control the flow of water across the river after a period of heavy rain. Crew member Ashley Tilling said a cruiser, which had sunk two weeks before, appeared on the day of the incident and could have impacted the water inquest also heard that the EA had planned to remove submerged boats from nearby Weir B, but the work had to be put on hold because of heavy rain in meant the weir was partially open, and Weir C, where the accident happened, was fully open. Another boat had also submerged on Weir C towards the end of September, the inquest Burns told the inquest: "Given the flow and immense pull of the water, it's my opinion it did not affect the boats in the channel."Although the inquest has ended, the verdict is expected to be given at a later Lawson's widow, Helen, said: "Peter's wonderful quirky blend of love, curiosity and kindness touched so many lives, and I shall remain forever grateful for the joy he brought into mine."Our families and friends hope lessons have been learned about improving emergency procedures and communication of potential dangers to river users."She added: "It seems very fitting that improved safety for river users will be his legacy to the rowing community."
